EDDP is the primary substance your body produces when it breaks down methadone. Its full chemical name is 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine, but in practice, you’ll almost always see it referred to simply as EDDP. It shows up most often in the context of urine drug testing, where its presence (or absence) tells clinicians whether someone has actually been taking methadone as prescribed.
How Your Body Creates EDDP
When you take methadone, your liver breaks it down through a process called N-demethylation. This creates a short-lived intermediate compound that quickly transforms into EDDP through a spontaneous chemical rearrangement. Several liver enzymes drive this conversion, with CYP2B6 playing the most significant role in real-world metabolism. Other enzymes, including CYP3A4, CYP2C19, and CYP2D6, also contribute.
Because EDDP can only exist in your body after methadone has been processed by your liver, it serves as proof that methadone was actually ingested and metabolized, not just present in a sample.
Why EDDP Matters on Drug Tests
Most people encounter the term EDDP on a urine drug test result, and its purpose is straightforward: it confirms that a person genuinely took methadone rather than adding it directly to a urine sample. This distinction matters in methadone treatment programs where patients are monitored for compliance.
Some patients have attempted to fake compliance by adding a small amount of their prescribed methadone liquid directly into a urine cup, a practice known as “spiking.” When this happens, the sample contains methadone but little to no EDDP. A legitimate sample from someone who swallowed their dose will contain both methadone and EDDP, because the liver had time to metabolize the drug. The absence of EDDP alongside the presence of methadone is a strong indicator that the sample was tampered with.
This is why many labs now test for both methadone and EDDP simultaneously rather than testing for methadone alone.
Detection Window and Cutoff Levels
EDDP is typically detectable in urine for about 7 days after the last methadone dose, though the actual window depends on how much methadone was taken, how frequently it was used, and individual differences in metabolism. People on daily maintenance doses will generally have consistently detectable levels.
Labs use different cutoff levels depending on the type of test. Screening immunoassays commonly use a cutoff of 300 nanograms per milliliter (ng/mL), meaning anything below that concentration is reported as negative. Confirmatory testing with more precise methods like liquid chromatography-mass spectrometry can detect EDDP at much lower concentrations, with some labs using a cutoff as low as 50 ng/mL.
What Affects EDDP Levels
Because EDDP is produced by specific liver enzymes, anything that speeds up or slows down those enzymes can change how much EDDP appears in your system. Medications that increase CYP2B6 activity (enzyme inducers) cause your body to convert methadone into EDDP faster, which can lower the amount of active methadone in your blood. Conversely, CYP2B6 inhibitors slow the conversion, potentially increasing methadone’s effects while reducing EDDP production.
Interestingly, research has shown that CYP3A4, long assumed to be the dominant enzyme in methadone metabolism, plays a smaller clinical role than originally thought. A pivotal study using a selective CYP2B6 inhibitor (ticlopidine) confirmed that CYP2B6 is the primary driver of methadone clearance in humans. This matters because some medications listed as CYP3A4 inhibitors, like the antiviral ritonavir, unexpectedly increased methadone clearance rather than decreasing it, defying predictions based on the older understanding of methadone metabolism.
Genetic differences also play a role. People with naturally more active versions of these enzymes (sometimes called rapid metabolizers) convert methadone to EDDP more quickly, which can mean their methadone wears off sooner and their EDDP levels run higher relative to methadone. Slow metabolizers show the opposite pattern.
False Positives and Test Accuracy
EDDP immunoassay tests are highly specific. According to FDA review data, the standard screening test at a 300 ng/mL cutoff shows virtually no cross-reactivity with other common drugs. Substances like doxylamine (a sleep aid), disopyramide (a heart medication), and even methadone itself would need to be present at concentrations more than 300 times the cutoff level to trigger a false positive on an EDDP-specific test. In practical terms, false positives from other medications are extremely rare with EDDP assays.
Common physiological substances found in urine, such as those from various medical conditions, have also been tested and shown no interference with EDDP results.
Sample Stability
If you’re wondering whether the way a sample is handled could affect results, EDDP is reasonably stable in urine. It remains intact at room temperature for at least 16 hours and stays stable when refrigerated for up to 72 hours. It also survives repeated freeze-thaw cycles without degrading. This means normal delays in sample processing are unlikely to cause a false negative from EDDP breaking down before it reaches the lab.